Skip to main content
OpenTrials
Completed

NCT Number: NCT00927277

Low Level Laser Light Therapy as an Aid to Liposuction

The purpose of this study is to determine whether low level laser therapy can help the recovery process for the procedure of liposuction of the thighs, hips and stomach.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The Erchonia EML Laser is designed to administer low level laser therapy (LLLT). It has been hypothesized that LLLT may reduce pain and promote nerve regeneration through the speculated anti-inflammatory and immune enhancement properties of the therapy. Prior research has indicated LLLT to be a potentially safe and effective means of reducing pain. This clinical study was designed to evaluate the potential of the Erchonia EML Laser in offering a novel means of delivering LLLT to reduce pain and enhance healing following liposuction.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

There were separate inclusion criteria for both the liposuction and the clinical study components of the study.

Inclusion criteria

FOR THE LIPOSUCTION PROCEDURE

Prior to partaking in the clinical study qualification evaluation, an individual must have already:

  • qualified as a patient for liposuction according to the American Society of Liposuction Surgery (ASLSS) and the American Academy of Cosmetic Surgery (AACS) 2000 Liposuction Guidelines.
  • been deemed suitable for undergoing anesthesia according to the American Society of Anesthesiologists: Preanesthesia Evaluation guidelines: Basic Standards For Preanesthesia Care (Approved by House of Delegates on October 14, 1987).
  • Signed the physician's standard informed consent form for the liposuction procedure itself.

Inclusion criteria

FOR THE CLINICAL STUDY

  • Signed clinical study informed consent form.
  • Liposuction procedure intended for the removal of localized deposits of adipose tissue for the purpose of body contouring.
  • Body Mass Index (BMI) in kg/m2 of less than 30 (non-obese).
  • Localized areas of protruding fat deemed suitable for body contouring liposuction according to the investigator's professional training and experience as for a patient presenting with the same profile and not being considered for participation in the study.
  • Areas of treatment to include only one or more of the right and/or left sides of the stomach, thigh, and hips.
  • 'Overall firm elastic skin,' as defined by passing of the "snap test" for each intended treatment area.
  • American Society of Anesthesiology (ASA) Physical Status Classification System rating of P1: a normal healthy patient or P2: a patient with mild systemic disease, as determined by standard physical examination.
  • Suitable for general intubation anesthesia.
  • 18 to 55 years, inclusive.

Exclusion criteria

  • Liposuction procedure intended for the treatment of diseases, such as lipomas, gynecomastia, pseudogynecomastia, lipodystrophy and axillary hyperhydrosis; for the reconstruction of the skin and subtissues in flap elevations, subcutaneous debulking, flap movement or other conditions; to obtain fat for fat transfer (for such purposes as augmentation, correction of scar defects, etc.), and for weight loss.
  • ASA Physical Status Classification System rating of P3 to P5.
  • Use of narcotics, opiates, steroids and/or NSAIDs within one week prior to surgery.
  • Any prior surgery to any of the area(s) to receive liposuction.
  • Active infection or wound in any part of the body, including the intended areas of treatment.
  • Arthritis or other disorders or injury that directly affect the areas to be treated, including any implants such as pins.
  • History of thrombotic events.
  • History of neurologic disorder e.g. sensory loss or dysthesia in any of the area(s) to be treated.
  • Diabetes.
  • Immuno-compromised state, e.g., HIV infection, radiation, chemo or other cancer therapy within the last 6 months.
  • Potential bleeding tendencies due to the use of aspirin, non-steroidal anti-inflammatory drugs, estrogen, Vitamin E, herbal supplements such as ginseng, ginger.
  • Potential hypercoagulability, e.g., tamoxifen therapy, cancer, recent significant trauma, dehydration.
  • Developmental disabilities that affect the ability to read and/or understand the consent form and any other information that may be required from the subject.
  • Significant psychological disorder(s) for which treatment has become necessary, including anxiety and depression; psychiatric hospitalization.
  • Pregnancy or lactation.
  • Involvement in litigation and/or receiving disability benefits related to any kind of disability, injury, or other problem in any one or more of the area(s) to receive liposuction.
  • Participation in research during the prior 90 days.

Treatment and study plan

Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser

Device

The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.

Erchonia(R) LipoLASER PL

Device

Primary outcomes

  1. Subject self-reported Degree of Pain rating on the standardized 0-100 Visual Analogue Scale (VAS) at 24 hours post-surgery.

    Time frame: 24 hours

Secondary outcomes

  1. Ease of the process of fat extraction during the liposuction procedure

    Time frame: immediately post surgery

  2. Emulsification (consistency) of extracted fat

    Time frame: immediately post surgery

  3. Amount of time spent by volume of fat removed

    Time frame: Immediately post surgery

  4. Degree of swelling at the surgical site

    Time frame: 7 days post surgery

  5. Subject self-reported degree of post-surgical pain

    Time frame: 7, 14 and 28 days post surgery

  6. Use of recovery pain medication

    Time frame: Through the 1st 7 post-surgical days

Sponsors and collaborators

Lead sponsor

Erchonia Corporation

Industry

Registry information

Official study title

Erchonia Medical, Inc., Erchonia EML Laser Liposuction Clinical Study V Protocol

Important dates

Study start
2003
Primary completion
2004
Study completion
2004
First posted
Jun 24, 2009
Registry last updated
Jun 26, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.